Role of IFNe in immune modulation and HIV infection

IFNe在免疫调节和HIV感染中的作用

基本信息

  • 批准号:
    10356898
  • 负责人:
  • 金额:
    $ 60.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-03-01 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

Project Summary Interferon e (IFNe) is a critical innate immune mediator that protects the host against sexually transmitted infections. Although the current paradigm is that IFNε is a type I IFN and signals through IFNa receptors, our and other published results show that IFNε has unique immune functions that are distinct from IFNa/b. IFNε is highly abundant in the mucosa of the female reproductive tract, and has superior mucosal immune activity compared to IFNa/b. IFNe gene expression is regulated by estrogen, cytokines, and seminal plasma, but is not induced by Toll-like receptor pathways, which induce IFNa/b. Clinical evidence indicates a protective role of IFNe against HIV. IFNe expression is positively associated with estrogen levels during the menstrual cycle, and inversely correlates with HIV susceptibility. Importantly, HIV-negative sex workers with frequent exposure to semen have an increased level of IFNe gene expression, and have increased numbers of immune effector cells in cervical tissues. We recently demonstrate that IFNe induces an anti-HIV state through a mechanism independent of known type I IFN-induced HIV host restriction factors in primary macrophages. Additionally, IFNε elicits a more robust immune response than IFNa2. We hypothesize is that IFNe displays a dual role in HIV inhibition by protecting HIV target cells and by modulating immune functions, and will test our hypothesis by determining the immune mechanism of IFNe and its impact on HIV infection in vitro, cervical explants and in humanized mouse model. To gain a better understanding of the molecular mechanism of IFNe-mediated HIV inhibition, we determine viral determinants important for IFNe sensitivity. Because estrogen is known to modulate IFNe expression and mucosal immunity, we will assess the impact of estrogen on IFNε-mediated processes in HIV infection in postmenopausal women before and after estrogen treatment. Elucidating the properties and functions of IFNe promises to expand our knowledge of virus-host interactions crucial for HIV prevention and control of viral reservoirs and immunopathogenesis.
项目总结

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro.
  • DOI:
    10.3390/pathogens10030272
  • 发表时间:
    2021-03-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Xu C;Wang A;Hoskin ER;Cugini C;Markowitz K;Chang TL;Fine DH
  • 通讯作者:
    Fine DH
Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry.
Brilacidin 是一种非肽防御素模拟分子,通过阻止病毒进入来抑制 SARS-CoV-2 感染。
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Xu,Chuan;Wang,Annie;Honnen,William;Pinter,Abraham;Weston,WarrenK;Harness,JaneA;Narayanan,Aarthi;Chang,TheresaL
  • 通讯作者:
    Chang,TheresaL
Multifaceted immune functions of human defensins and underlying mechanisms.
人防御素和潜在机制的多方面免疫功能。
Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms.
  • DOI:
    10.3390/v13060953
  • 发表时间:
    2021-05-21
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Xu C;Wang A;Geng K;Honnen W;Wang X;Bruiners N;Singh S;Ferrara F;D'Angelo S;Bradbury ARM;Gennaro ML;Liu D;Pinter A;Chang TL
  • 通讯作者:
    Chang TL
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Theresa L Chang其他文献

Theresa L Chang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Theresa L Chang', 18)}}的其他基金

Sex difference in intestinal immune dysfunction, SHIV infection and reservoir
肠道免疫功能障碍、SHIV感染和储存者的性别差异
  • 批准号:
    10654740
  • 财政年份:
    2021
  • 资助金额:
    $ 60.28万
  • 项目类别:
Impact of gender affirming hormone therapy on immune modulation and HIV infection in transgender young adults
性别肯定激素治疗对跨性别年轻人免疫调节和艾滋病毒感染的影响
  • 批准号:
    10364706
  • 财政年份:
    2021
  • 资助金额:
    $ 60.28万
  • 项目类别:
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir
肠道免疫功能障碍、SHIV感染和储存者的性别差异
  • 批准号:
    10462764
  • 财政年份:
    2021
  • 资助金额:
    $ 60.28万
  • 项目类别:
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir
肠道免疫功能障碍、SHIV感染和储存者的性别差异
  • 批准号:
    10327456
  • 财政年份:
    2021
  • 资助金额:
    $ 60.28万
  • 项目类别:
Impact of gender affirming hormone therapy on immune modulation and HIV infection in transgender young adults
性别肯定激素治疗对跨性别年轻人免疫调节和艾滋病毒感染的影响
  • 批准号:
    10257722
  • 财政年份:
    2021
  • 资助金额:
    $ 60.28万
  • 项目类别:
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera
Depo-Provera 对先天免疫、微生物组和 HIV 传播的调节
  • 批准号:
    9045100
  • 财政年份:
    2013
  • 资助金额:
    $ 60.28万
  • 项目类别:
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera
Depo-Provera 对先天免疫、微生物组和 HIV 传播的调节
  • 批准号:
    8716673
  • 财政年份:
    2013
  • 资助金额:
    $ 60.28万
  • 项目类别:
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera
Depo-Provera 对先天免疫、微生物组和 HIV 传播的调节
  • 批准号:
    8885647
  • 财政年份:
    2013
  • 资助金额:
    $ 60.28万
  • 项目类别:
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera
Depo-Provera 对先天免疫、微生物组和 HIV 传播的调节
  • 批准号:
    8593906
  • 财政年份:
    2013
  • 资助金额:
    $ 60.28万
  • 项目类别:
HIV-Human Peritonal Macrophage Interactions
HIV-人腹膜巨噬细胞相互作用
  • 批准号:
    8232027
  • 财政年份:
    2011
  • 资助金额:
    $ 60.28万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 60.28万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了